Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-02-06 am EST			5-day change	1st Jan Change
80.36 ^EUR	-0.90%		+1.46%	-2.85%

Feb. 06	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
Feb. 05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI

Sanofi reduces valuation after R&D setbacks

AlphaValue lowers its NAV and DCF for Sanofi after late-stage disappointments in Immunology and neuroscience, revising medium-term growth assumptions. While M&A activity accelerates, investors await bolder strategic moves as Dupixent dominance persists and balance sheet capacity remains solid.

Published on 12/31/2025 at 01:03 am EST

Alphavalue

This article is reserved for subscribers.

Alphavalue, the European leader in independent research, is exclusively available on MarketScreener.

To unlock the article, subscribe!

Latest news about Sanofi

Feb. 06	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
Feb. 05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI
Feb. 04	ETFs: how to bet on European value?
Feb. 03	Sanofi's Rezurock Expands Provincial Access in Canada	MT
Feb. 03	Sanofi - Rezurock now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (Gvhd)	RE
Feb. 03	Sanofi Launches $1.18 Billion Share Buyback Program	MT
Feb. 03	Amundi, Publicis, Sartorius... Key Stocks to Watch Today in Paris
Feb. 03	Sanofi to Buy Back Up to €1 Billion of Its Own Shares in 2026
Feb. 03	Sanofi Kicks Off Up to EUR1 Billion Share Buyback	MT
Feb. 03	Sanofi signs share buyback mandate for up to EUR 1 bln	RE
Feb. 02	Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says	MT
Feb. 02	European Stocks Track Higher in Monday Trading; Eurozone Manufacturing Continues to Contract	MT
Feb. 02	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Precious Metals Downturn	MT
Feb. 02	UK industry body says Sanofi in breach over RSV therapy claims against Pfizer	RE
Feb. 02	Sanofi Found by UK Regulator in Breach of Pharmaceutical Industry Code	MT
Feb. 02	UK Pharma Industry Body Reprimands Sanofi After Pfizer's Complaint	MT
Feb. 02	Sanofi Rises After Phase 3 Data and Oddo BHF Rating
Feb. 02	Sanofi Says Venglustat Meets Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease	MT
Feb. 02	Capgemini, Sanofi, Eramet... Stocks to Watch Today in Paris
Feb. 02	Positive Results for Sanofi in Gaucher Disease
Feb. 02	Sanofi Posts Positive Results from Phase 3 Study for GD3 Treatment	MT
Feb. 02	Sanofi's venglustat met all primary endpoints in a phase 3 study	RE
Feb. 02	Sanofi's genetic disorder drug shows mixed results in late-stage trials	RE
Feb. 02	Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease	CI
Feb. 01	EU must push for 'Made in Europe' strategy, EU industry chief says	RE

Chart Sanofi

Duration

Period

SAN: Dynamic Chart

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Employees

82,878

Sector

Pharmaceuticals

Calendar

Apr. 22 - Q1 2026 Earnings Call

More about the company